Endocrine Abstracts

Introduction: Lenvatinib is a multitarget tyrosine kinase inhibitor that has shown substantial efficacy in patients with progressive radioiodine refractory thyroid cancer (RAIRDTC) (progression free survival (PFS) 19.4 months and objective response rate 64.8%; SELECT trial) despite common adverse events (AEs).Objective: To evaluate efficacy and toxicity of lenvatinib treatment for RAIRDTC in daily clinical practice.Methods: Retrosp...

Introduction: Diamond-Blackfan anemia (DBA) is a severe congenital erythroid aplastic anemia with autosomal dominant inheritance. It is a rare disease (incidence 1/150000) and usually is discovered during the 2 first years after birth. Treatment includes steroids, blood transfusions and bone-marrow transplantation.Case report: A 31 year-old woman with DBA had received multiple treatments including transfusion support since birth. Consequently, she had de...